Breaking Down North China Pharmaceutical Company Ltd. Financial Health: Key Insights for Investors

North China Pharmaceutical Company Ltd. (600812.SS) presents a mixed financial picture that investors should scrutinize: H1 2025 revenue of CNY 5.275 billion (up 0.84% YoY) and TTM revenue of CNY 9.79 billion versus FY2024 revenue of CNY 9.87 billion, while quarterly revenue for Sept 2025 slipped to CNY 2.21 billion (down 5.12% YoY); profitability shows H1 2025 net income attributable to shareholders of CNY 123 million (a 71.56% increase YoY) and TTM net income of CNY 178.51 million with a net margin of 1.80% and EPS (TTM) of CNY 0.10 (trailing P/E 57.13); the balance sheet and liquidity raise flags-total assets of CNY 21.54 billion, liabilities CNY 14.86 billion, equity CNY 6.67 billion for a debt-to-equity ratio of 1.62, current ratio 0.71 and quick ratio 0.49, total debt CNY 10.89 billion and net cash of -CNY 9.29 billion-cash and short-term investments stand at CNY 1.61 billion (down 6.77% YoY) while operating cash flow (TTM) is CNY 837.88 million, capex CNY 691.16 million and free cash flow CNY 146.72 million; valuation multiples include market cap CNY 9.80 billion, enterprise value CNY 20.74 billion (EV/EBITDA 13.04, EV/FCF 141.35, P/S 1.00, P/B 1.52) and a low-beta 0.38, but solvency metrics such as an Altman Z-Score of 0.74 and interest coverage of 1.68 underscore elevated bankruptcy risk, even as a Piotroski F-Score of 6 and strategic moves into biologics, efficiency upgrades and demographic tailwinds suggest potential catalysts-read on for a deep dive into these figures, operational risks (regulatory pressures, competition, commodity-driven earnings volatility, supply-chain and environmental concerns) and what they mean for near-term investor decisions.

North China Pharmaceutical Company Ltd. (600812.SS) - Revenue Analysis

• H1 2025 revenue: CNY 5.275 billion - +0.84% vs H1 2024
• TTM revenue: CNY 9.79 billion - +0.91% year-over-year
• Full-year 2024 revenue: CNY 9.87 billion - -2.48% vs 2023
• Q3 (Sep) 2025 revenue: CNY 2.21 billion - -5.12% vs Q3 2024

• Revenue per employee: ~CNY 970,870 (10,088 employees)
• Market capitalization: CNY 9.80 billion
• Price-to-sales (P/S): 1.00

• Small positive growth on a TTM and H1 basis contrasts with annual decline in 2024 and a weaker Q3 2025, indicating near-term seasonality or product/market headwinds.
• Revenue per employee (~CNY 0.97M) suggests moderate operational efficiency relative to peer pharmaceutical labor intensity; monitor trend vs future headcount changes.
• P/S of 1.00 implies the market values the company at roughly one year of sales - a neutral starting point for valuation comparisons within the sector.

North China Pharmaceutical Company Ltd. (600812.SS) - Profitability Metrics

Key profitability indicators for North China Pharmaceutical Company Ltd. (600812.SS) show improving bottom-line performance in H1 2025 alongside modest margins and shareholder returns. The data below highlights recent earnings, margin structure, and per-share metrics relevant for investors assessing earnings quality and valuation.

• Net income attributable to shareholders (H1 2025): CNY 123.00 million (up 71.56% YoY)
• Trailing twelve months (TTM) net income: CNY 178.51 million
• TTM net profit margin: 1.80%
• TTM earnings per share (EPS): CNY 0.10
• Trailing P/E ratio: 57.13
• Operating margin: 6.94%
• EBITDA margin: 15.48%
• Return on equity (ROE): 4.21%
• Return on assets (ROA): 1.98%
• Annual dividend per share: CNY 0.03
• Dividend yield: 0.51%

Margins indicate that while operating profitability (6.94%) and EBITDA conversion (15.48%) are reasonable for a pharmaceutical manufacturer, net margin (1.80%) and ROE (4.21%) remain low relative to growth in absolute net income. EPS and the high trailing P/E (57.13) reflect limited earnings per share vs. market pricing, and the dividend yield (0.51%) suggests a conservative cash return policy.

For broader context on the company's history, ownership and business model, see: North China Pharmaceutical Company Ltd.: History, Ownership, Mission, How It Works & Makes Money

North China Pharmaceutical Company Ltd. (600812.SS) - Debt vs. Equity Structure

• Total assets: CNY 21.54 billion (as of Sep 2025)
• Total liabilities: CNY 14.86 billion
• Total equity: CNY 6.67 billion
• Total debt: CNY 10.89 billion
• Net cash position: -CNY 9.29 billion (net debt)

• Liquidity concern: Current ratio 0.71 and quick ratio 0.49 indicate potential near-term funding pressure unless working capital improves or financing is secured.
• Leverage concern: Debt-to-equity of 1.62 and total debt CNY 10.89 billion mean interest and principal obligations are sizable relative to equity.
• Interest-service risk: Interest coverage at 1.68 leaves limited room for profit volatility or higher rates.
• Valuation context: P/B of 1.52 suggests the market assigns a premium to book value despite leverage and liquidity signals.

North China Pharmaceutical Company Ltd. (600812.SS) - Liquidity and Solvency

Key liquidity and solvency indicators for North China Pharmaceutical Company Ltd. (600812.SS) highlight constrained cash buffers, modest free cash generation, and elevated bankruptcy risk per the Altman model, alongside a middling Piotroski score that suggests mixed operational/financial signals. Relevant contextual analysis and figures follow.

• Cash & short-term investments: CNY 1.61 billion (down 6.77% year-over-year).
• Operating cash flow (TTM): CNY 837.88 million.
• Capital expenditures (TTM): CNY 691.16 million.
• Free cash flow (TTM): CNY 146.72 million (Operating CF - CapEx).
• Net change in cash (quarter ended 2025-09-30): CNY 106.73 million, a 292.73% increase YoY.
• Effective tax rate: 32.70%; income tax payments (past 12 months): CNY 94.10 million.
• Altman Z-Score: 0.74 (indicates higher bankruptcy risk).
• Piotroski F-Score: 6 (moderate financial health).

Implications for stakeholders:

• Liquidity: CNY 1.61bn cash buffer has contracted; positive quarterly net cash change (+CNY 106.73m) partially offsets the YoY decline.
• Cash generation vs. investment: Positive but slim FCF (CNY 146.72m) after heavy capex, limiting discretionary capacity for deleveraging or shareholder returns.
• Credit/insolvency risk: Altman Z-Score at 0.74 signals elevated bankruptcy risk - creditors and investors should treat leverage and short-term obligations cautiously.
• Operational/quality signal: Piotroski F-Score of 6 implies some fundamental strengths but room for improvement in profitability, efficiency, or balance-sheet quality.
• Tax cash outflows: Effective tax rate of 32.70% with CNY 94.10m paid in the last 12 months is a notable ongoing cash drain to model in forecasts.

For broader corporate context and strategic background that complements these liquidity and solvency metrics, see North China Pharmaceutical Company Ltd.: History, Ownership, Mission, How It Works & Makes Money

North China Pharmaceutical Company Ltd. (600812.SS) - Valuation Analysis

• Trailing P/E: 57.13
• P/S: 1.00
• P/B: 1.52
• EV/Revenue: 2.09
• EV/EBITDA: 13.04
• EV/FCF: 141.35
• Market capitalization: CNY 9.80 billion
• Enterprise value (EV): CNY 20.74 billion
• 52-week price change: -0.84%
• Beta: 0.38

• The high trailing P/E (57.13) signals investors are paying a significant premium for current earnings-consistent with growth expectations or near-term margin pressures reducing trailing earnings.
• P/S of 1.00 and P/B of 1.52 indicate the market values sales and book equity modestly above replacement or historical norms, suggesting neither deep discount nor extreme premium on those bases.
• EV/EBITDA at 13.04 is in a mid-range band-neither bargain-level nor frothy-while EV/FCF at 141.35 highlights relatively weak free-cash-flow generation versus enterprise value, warranting scrutiny of cash conversion.
• A market cap of CNY 9.80 billion versus EV of CNY 20.74 billion shows meaningful net debt or minority interests factored into total valuation (EV > market cap).
• Low beta (0.38) and a minor 52-week decline (-0.84%) indicate lower volatility and relative price stability versus broader market swings.

North China Pharmaceutical Company Ltd. (600812.SS) - Risk Factors

• Regulatory risk: heavy oversight from China's National Medical Products Administration (NMPA) and tightening environmental rules increase approval timelines and capital expenditures for compliance.
• Competitive pressure: intense competition in generics (especially antibiotics) and bulk vitamins from domestic peers and multinational firms compresses margins and market share.
• Commodity-driven earnings volatility: products like vitamin C have historically exhibited sharp price cycles that materially swing revenue and gross margin.
• Operational concentration: significant exposure to antibiotic and vitamin manufacturing creates demand risk (e.g., shifts due to antibiotic resistance policies, stewardship programs, or substitution).
• Supply chain & environmental incidents: past industry reports cite disruptions (raw-material tightness, logistics delays) and environmental non-compliance events that can trigger fines, production halts or remediation costs.
• Financial distress indicator: an Altman Z-Score of 0.74 signals elevated bankruptcy risk and limited cushion against shocks.

• Investor considerations:
  • Stress-test valuation for prolonged low commodity prices and slower product approvals.
  • Monitor disclosures on environmental investments, fines, or enforced production stoppages.
  • Track product mix shifts away from high-risk antibiotic exposure or toward higher-margin innovative lines.

North China Pharmaceutical Company Ltd. (600812.SS) - Growth Opportunities

• Strategic focus: management guidance and annual report state prioritization of high-value biologics (biosimilars, recombinant proteins) and specialty chemical intermediates to capture higher margins.
• Operational efficiency: planned CAPEX and technological upgrades (automation, process analytical technology, digital manufacturing) target lower COGS and higher throughput.
• Demographic & policy tailwinds: China's aging population and central/local policies favoring domestic pharmaceutical self-sufficiency support long-term demand for both chronic-disease biologics and essential APIs.
• Market context: global antibiotic and vitamin markets remain mature and competitive; stable demand but margin pressure implies value from moving upstream into differentiated biologics and specialty chemicals.
• Catalysts to monitor: upcoming quarterly/annual earnings releases, regulatory approvals for new generics/production expansions, and any capacity-addition announcements that may re-rate cash flow expectations.

• Investment implications: a shift toward biologics and specialty chemicals can materially improve gross margins (target +3-6 percentage points over 2-3 years if execution succeeds), but requires near-term CAPEX and potential R&D ramp costs.
• Balance-sheet context: Piotroski F‑Score of 6 indicates the company exhibits several favorable accounting and performance signals (profitability, liquidity, modest leverage) but still leaves room for operational improvement and cash-flow consistency.
• Risk factors: execution risk on biologics scale-up, regulatory timing for product approvals, and competitive pressure in antibiotics/vitamins could compress near-term margins if demand or pricing weakens.
• Near-term catalysts to watch:

• Regulatory approvals for new generics or biologic manufacturing lines (NMPA filings/approvals).
• Quarterly sales growth in higher-margin biologics/specialty chemical segments (% mix increase month-on-month or year-on-year).
• Announcements of technological upgrades or successful pilot production runs showing yield improvements.
• Cash-flow conversion improving alongside reductions in working capital days.